Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
All-Trans-Retinoic Acid Differentially Regulates Proliferation of Normal and Leukemic B Cells From Different Subsets of Chronic Lymphocytic Leukemia Publisher Pubmed



Ghalamfarsa G1, 2 ; Jadidiniaragh F1 ; Amiri MM3 ; Razavi SM4 ; Sabooryaraghi AA5 ; Shokri F1, 3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Immunology Research Center, Medical School, Mashhad University of Medical Sciences, Mashhad, Iran
  3. 3. Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
  4. 4. Clinic of Hematology and Oncology, Tehran University of Medical Sciences, Firozgar Hospital, Tehran, Iran
  5. 5. Department of Nutrition, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Source: Nutrition and Cancer Published:2015


Abstract

All-trans-retinoic acid (ATRA) has been shown to modulate cell growth and differentiation in a variety of tumor cell types, but little is known regarding its precise role in regulation of leukemic B cells from different subsets of chronic lymphocytic leukemia (CLL). Previously, we showed that IL-21 significantly inhibits the CpG-mediated proliferation of CLL B cells in progressive compared to nonprogressive patients. In the present study, the effect of ATRA (10-7mol/L) on in vitro proliferation and apoptosis of B cells was investigated in 24 CLL patients and 8 normal subjects. Our results showed that ATRA markedly enhanced CpG-mediated proliferation of normal B cells, but it slightly inhibited CpG-induced proliferation of CLL B cells [stimulation index (SI): 105.6 vs. 14.7, P = 0.0001]. Although addition of IL-21 counteracted the proliferative effect of ATRA in normal B cells, it significantly enhanced the growth of tumor B cells in presence of CpG and ATRA. This stimulatory effect was restricted to nonprogressive and unmutated patients compared to progressive and mutated groups, respectively. Our results suggest that ATRA acts differentially on normal and CLL B cells and might have therapeutic implication in patients with progressive disease. © 2015 Copyright © 2015 Taylor & Francis Group, LLC.